Caspofungin versus Liposomal Amphotericin B for Empirical Therapy
|
|
- Brittany Spencer
- 6 years ago
- Views:
Transcription
1 correspondence Caspofungin versus Liposomal Amphotericin B for Empirical Therapy THIS WEEK S LETTERS 410 Caspofungin versus Liposomal Amphotericin B 414 Single-Dose Azithromycin for Trachoma 415 Controlling Health Care Costs 416 Bell s Palsy 418 Pulmonary Hypertension 419 Case : A Woman with Paresthesias 420 Increased Serum Lipase in West Nile Virus Infection to the editor: In the important study by Walsh et al. (Sept. 30 issue), 1 the most unexpected finding was the difference in response rates between the liposomal amphotericin B group and the caspofungin group among patients who had aspergillosis at baseline. The rate of response to liposomal amphotericin B (8.3 percent) is the lowest ever reported in the treatment of aspergillosis. This finding raises the question of whether there were imbalances between the treatment groups in terms of host factors (i.e., neutrophil recovery) or prior use of azole therapy, since sequential therapy with itraconazole and amphotericin B has been shown to attenuate the efficacy of amphotericin B, 2 and sequential itraconazole and caspofungin enhances the activity of caspofungin against aspergillus. 3 The poor response may also have been influenced by the arbitrary definition of breakthrough infections as those occurring on the third day of therapy or later; the presence of aspergillus galactomannan antigen is usually confirmed after several days of clinical evidence of aspergillosis in patients with leukemia who have fever and neutropenia, 4 and antifungal agents may require more than 72 hours to reach effective concentrations in tissue. 5 Investigators designing future studies should consider these issues in defining what really constitutes a breakthrough fungal infection. Dimitrios P. Kontoyiannis, M.D. Russell E. Lewis, Pharm.D. University of Texas M.D. Anderson Cancer Center Houston, TX dkontoyi@mdanderson.org Dr. Kontoyiannis reports having served on an advisory board for Schering-Plough and having received honoraria and research support from and served on speakers bureaus for Merck, Pfizer, Fujisawa, and Enzon; Dr. Lewis reports having received research support from Merck, Fujisawa, and Pfizer and having served on advisory boards for Pfizer and Schering-Plough. 1. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351: Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002;46: Kontoyiannis DP, Lewis RE, Lionakis MS, Albert ND, May GS, Raad II. Sequential exposure of Aspergillus fumigatis to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diagn Microbiol Infect Dis 2003;47: Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 3)- beta-d-glucan test in weekly screening for invasive aspergillosis in patients treated with hematological disorders. J Clin Microbiol 2004;42: Becker MJ, de Marie S, Fens MH, Hop WC, Verbrugh HA, Bakker- Woudenberg IA. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002;49: to the editor: In their large study of caspofungin as compared with liposomal amphotericin B for em- 410
2 correspondence pirical antifungal therapy in patients with persistent fever and neutropenia, Walsh et al. observed an unexpectedly low rate of resolution of baseline fungal infections in the liposomal amphotericin B group 25.9 percent; the rate was 66.7 percent when liposomal amphotericin B was compared with voriconazole 1 and 81.8 percent when it was compared with conventional amphotericin B in two very similar previous studies. 2 Although historical comparisons are not valid, such an unexpectedly high failure rate deserves further investigation. In the current study, 56.4 percent of the patients were receiving systemic antifungal prophylaxis at baseline; systemic antifungal prophylaxis is now commonly used at increasing dosages (e.g., fluconazole at 400 mg per day) for high-risk patients. Because amphotericin B exerts its antifungal effect by binding to ergosterol, previous prolonged exposure to azoles that has reduced ergosterol concentrations in the fungal cytoplasmic membrane could modify fungal susceptibility to amphotericin B. 3 Did the authors compare the rate of response of baseline fungal infections to liposomal amphotericin B between patients who had previous azole exposure and those who did not? Pierre Tattevin, M.D. Benoît Bareau, M.D. Christophe Camus, M.D. Pontchaillou University Hospital Rennes, France pierre.tattevin@chu-rennes.fr 1. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340: Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995;39: to the editor: Walsh and colleagues report the noninferiority of caspofungin to liposomal amphotericin B when given empirically in patients with fever and neutropenia but report a lower overall survival rate and worse outcomes among patients with baseline fungal infections (in most cases, invasive aspergillosis) who were assigned to treatment with liposomal amphotericin B. The trial used liposomal amphotericin B at a dose of 3 mg per kilogram of body weight per day, with an increase to 5 mg per kilogram per day after five days if the clinical response was not adequate. Current practice is to treat invasive aspergillosis with voriconazole, 1 liposomal amphotericin B at a dose of 5 mg per kilogram per day or higher, 2,3 or caspofungin at the doses used in the trial. Thus, patients in the liposomal amphotericin B group who had baseline invasive aspergillosis may have received suboptimal doses of that drug at a time when frontloading 4 of therapy is critical to gain control of the infection. This situation may account for the differences observed in the prespecified end points. We would like to know whether the overall difference in survival shown by the Kaplan Meier curves persisted after patients with baseline fungal infections were excluded from the analysis. Therapeutic prescriptions beyond empirical therapy need to be studied in this population. Francisco M. Marty, M.D. Colleen M. Lowry, Pharm.D. Brigham and Women s Hospital Boston, MA fmarty@partners.org Dr. Marty reports having received research support from Fujisawa. 1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347: Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30: Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45: Baden LR, Teplick R, Rubin RH. Antimicrobial therapy. In: Parrillo JE, Dellinger RP, eds. Critical care medicine: principles of diagnosis and management in the adult. St. Louis: Mosby, 2001: to the editor: Walsh et al. report the noninferiority of caspofungin to liposomal amphotericin B when given as empirical therapy in patients with fever and neutropenia. Both caspofungin and liposomal amphotericin B are expensive drugs, costing more than $500 per day. We use conventional amphotericin B deoxycholate, given as a continuous infusion over a 24-hour period, as standard empirical therapy in patients with fever and neutropenia. The infusion is administered with the use of multilumen central venous catheters, one of which is reserved for continuous infusion of amphotericin B deoxycholate. This approach has been shown to be less toxic than, and as effective as, standard short-term infusion of amphotericin B 1-4 ; the efficacy and tox- 411
3 icity are in the range of those reported for liposomal amphotericin B. 1,2 Continuous infusion of amphotericin B deoxycholate costs about $50 per day. The use of this approach instead of liposomal amphotericin B or caspofungin saves our medical center more than $400,000 per year in medication expenses. Hospitals with tight budgets should weigh the differences in cost for these equally effective drugs. Markus Schneemann, M.D. Alexander Imhof, M.D. University of Zurich Medical School CH-8091 Zurich, Switzerland markus.schneemann@usz.ch Dr. Schneemann reports having received lecture fees and travel grants from Merck Sharp & Dohme (Europe), Pfizer, and Bristol- Myers Squibb; Dr. Imhof reports having received lecture fees and travel grants from Merck, Pfizer, Gilead, and Bristol-Myers Squibb. 1. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322: Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36: Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B deoxycholate as a continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132: Speich R, Dutly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002;132: to the editor: In his editorial accompanying the report by Walsh et al., Klastersky 1 states that there is current evidence that voriconazole and caspofungin are suitable, and possibly preferable, alternatives to amphotericin B deoxycholate and liposomal amphotericin B as empirical antifungal therapy in patients with persistent fever and neutropenia. He suggests that a head-to-head comparison may reveal one to be a more rational choice. He neglects to mention a study by Eriksson et al., 2 who showed that administration of 1 mg of amphotericin B per kilogram per day over a 24-hour period, instead of the conventional 4-hour period, was associated with a dramatic decrease in nephrotoxic and infusionrelated side effects. More strikingly, there was a decrease in mortality, the most concrete of end points, in the continuous-infusion group. Given the wide discrepancy in the costs of the available agents, this finding warrants further research. Specifically, for a 70-kg person, the cost per day of maintenance intravenous therapy is as follows: amphotericin B (1 mg per kilogram), $17; voriconazole (4 mg per kilogram), $298; and caspofungin (50 mg), $ A larger study confirming the efficacy and tolerability of continuous-infusion amphotericin B may show that it is the most rational choice. (The opinions and assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the official policy of the Department of Defense or other departments of the U.S. government.) Patrick J. Danaher, M.D. David Grant U.S. Air Force Medical Center Travis AFB, CA patrick.danaher@travis.af.mil 1. Klastersky J. Antifungal therapy in patients with fever and neutropenia more rational and less empirical? N Engl J Med 2004; 351: Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322: Antifungal therapy cost analysis. (Accessed January 6, 2005, at to the editor: We urge caution regarding Klastersky s suggestion that antifungal agents should be reserved for patients with probable infection. Early initiation of antifungal therapy, when the fungal burden is low, plays a crucial role in improving survival. 1 As Klastersky asserts, the identification of patients at highest risk for invasive fungal infection is critical. Risk stratification may be further refined with the use of sensitive diagnostic tools such as an enzyme-linked immunosorbent assay for galactomannan and a polymerase-chain-reaction (PCR) assay for fungal genomic DNA to screen high-risk patients prospectively for early evidence of fungal infection. These assays have excellent negative predictive values, and they may be used to determine whether antifungal therapy can be withheld in patients who have antibiotic-resistant neutropenic fever with no other evidence of invasive fungal infection. 2 However, we believe that the real issue is how to treat patients earlier. Positive results of PCR and aspergillus galactomannan assays are often recorded before the development of fever, which is the trigger for empirical therapy. 2 These techniques may 412
4 correspondence allow earlier initiation of therapy, shifting the emphasis from empirical to preemptive therapy, with the potential for an improved outcome. This concept merits further investigation. Brian L. Jones, M.B., Ch.B. Glasgow Royal Infirmary Glasgow G4 0SF, United Kingdom Lorna A. McLintock, M.B., Ch.B. University of Glasgow Glasgow G31 2ER, United Kingdom 1. Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977;86: McLintock LA, Jones BL. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol 2004;126: dr. walsh and colleagues reply: In collaboration with Dr. Hedy Teppler and Merck Research Laboratories, we conducted additional analyses to address the correspondents questions. In addressing the questions of Drs. Kontoyiannis and Lewis, we note that several factors may have affected the rate of response of baseline invasive fungal infections. The data on the response of invasive aspergillosis to liposomal amphotericin B in patients with profound neutropenia are sparse and noncomparative, thus making comparisons difficult. The blinded review and assessments of the therapeutic response in this trial applied to all cases a uniform definition of breakthrough invasive fungal infection: infection on day 3 of therapy or later. Patients with baseline invasive fungal infections in the two treatment groups were balanced with respect to the underlying disease, the risk category, the proportion with previous exposure to antifungal prophylaxis, and the proportion with profound neutropenia. The duration of neutropenia during the study among patients with baseline invasive fungal infections was also similar between the two groups. After enrollment, the mean (±SEM) time to neutrophil recovery among patients whose neutropenia resolved before the end of therapy was 8.3±1.3 days in the caspofungin group as compared with 9.5±1.7 days in the liposomal amphotericin B group (P=0.56). Among patients whose study therapy was discontinued while they still had neutropenia, the mean duration of neutropenia was at least 7.9±1.7 days in the caspofungin group and 8.7±1.1 days in the liposomal amphotericin B group (P=0.66). Because patients data were censored at the end of therapy, the time to neutrophil recovery in these patients is not known. In response to Drs. Marty and Lowry: we used the approved dosage of liposomal amphotericin B for empirical antifungal therapy 3 mg per kilogram per day. When our clinical trial was designed and initiated, in 1999, voriconazole had not been approved for the primary treatment of invasive aspergillosis. At the time of enrollment, no patient had a documented invasive fungal infection. Liposomal amphotericin B is approved for salvage treatment of invasive aspergillosis at a dosage of 3 to 5 mg per kilogram per day in the United States and at 3 mg per kilogram per day in most countries in Europe. Other groups have advocated liposomal amphotericin B dosages for the treatment of invasive aspergillosis of 1 mg per kilogram per day, 1 4 mg per kilogram per day, 2 or at least 5 mg per kilogram per day. 3 Thus, given the regulatory and clinical considerations with respect to liposomal amphotericin B dosage, use of 3 mg per kilogram per day was the most tenable initial dosing strategy. Finally, when the Kaplan Meier survival curves were plotted for patients in the modified intentionto-treat population who did not have a baseline invasive fungal infection, the pattern of the curves was similar but the log-rank chi-square was not significant (P=0.29), indicating that there was no difference between the treatment groups with respect to survival among patients without a baseline invasive fungal infection. In response to Dr. Tattevin and colleagues: we did not see increased resistance to therapy among patients who had previously received azole prophylaxis. For patients with documented baseline invasive fungal infections, the proportion with a successful outcome was 46.2 percent (6 of 13) in the caspofungin group versus 23.1 percent (3 of 13) in the liposomal amphotericin B group, among those who received azole prophylaxis, and 57.1 percent (8 of 14) in the caspofungin group versus 28.6 percent (4 of 14) in the liposomal amphotericin B group, among those who received no prophylaxis. Because the pharmacodynamics of the efficacy of amphotericin B deoxycholate are thought to be concentration-dependent rather than time- 413
5 dependent, 4,5 so the continuous-infusion method proposed by Drs. Schneemann and Imhof seems counterintuitive. No clinical trial of continuous infusion has had sufficient power to demonstrate equal efficacy between continuous infusion and intermittent infusion of amphotericin B deoxycholate. Thomas J. Walsh, M.D. National Cancer Institute Bethesda, MD Gerald R. Donowitz, M.D. University of Virginia Health System Charlottesville, VA Ben E. depauw, M.D., Ph.D. University Hospital St. Radboud 6525 GA Nijmegen, the Netherlands 1. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27: Karp JE, Merz WG. Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward. Clin Infect Dis 1998;27: Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45: Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001;45: Van der Auwera P, Ceuppens AM, Heymans C, Meunier F. In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrob Agents Chemother 1986;29: Single-Dose Azithromycin for Trachoma to the editor: Solomon et al. (Nov. 4 issue) 1 suggest that the ocular chlamydia that causes trachoma can be eliminated by a single mass antibiotic treatment. Two years after distributing oral azithromycin in a village, they identified only a single infection. The authors state that this finding contrasts starkly with the prediction of our mathematical model. 2,3 Yes and no. We do predict that infection will eventually return after a single mass treatment. However, with 97.5 percent coverage of a moderately infected area, this return may take a long time. Our model predicts that less than 3 percent of persons will be infected at one year and an even smaller proportion in this case, since Solomon et al. also distributed tetracycline ointment. Furthermore, this estimate is only an expectation (or average), and chance can have a large effect. We recently monitored 24 villages in Ethiopia after a single mass treatment; in some villages, infection was eliminated at two months, and in others it returned relatively rapidly. 3 Unfortunately, the evidence so far suggests that, on average, infection returns after a single mass treatment, but to test this properly, one must look at more than one village. Thomas M. Lietman, M.D. Bruce Gaynor, M.D. University of California, San Francisco San Francisco, CA tml@itsa.ucsf.edu Travis Porco, Ph.D. California Department of Health Services Berkeley, CA Solomon AW, Holland MJ, Alexander NDE, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004;351: Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999;5: Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA 2004;292: the authors reply: Two main factors differentiate our study from the model of Lietman et al. 1 First, our primary outcome measure was an adjusted geometric mean of the ocular Chlamydia trachomatis load, determined with the use of a quantitative polymerase-chain-reaction assay. The model, in contrast, used the prevalence of active trachoma, which correlates poorly with chlamydial infection. 2 Second, we reported that after high-coverage mass treatment, the load of infection dropped and then continued to fall for at least two years, whereas the model predicted that (in communities like ours, where the disease is mesoendemic) the prevalence of disease would double every four to eight months after a treatment-induced fall. Our results suggest that there may be a threshold level of infection, below which the transmission of trachoma ceases; its return might then depend on reintroduction from the outside by persons with heavy shedding of C. trachomatis. We agree that our data are from only a single community case study but note that six months after mass treatment, six Ethiopian villages studied by Lietman s group had a prevalence of infection of 414
amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationInvasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used on demand?
Original article Peer reviewed article SWISS MED WKLY 25;135:624 63 www.smw.ch 624 Invasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationMicafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia
ORIGINAL ARTICLE Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia Masamitsu Yanada 1,2, Hitoshi Kiyoi 2, Makoto Murata 1, Momoko Suzuki 1,
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCombination Antifungal Therapy for Invasive Aspergillosis
MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT
The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL AND LIPOSOMAL
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationInvasive aspergillosis (IA) is a leading cause of infectious death in
292 Efficacy and Toxicity of Caspofungin in Combination with Liposomal Amphotericin B as Primary or Salvage Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancies Dimitrios P. Kontoyiannis,
More informationTitle: Empirical Therapy with Echinocandins for Suspected Candidemia and Invasive Candidiasis: A Clinical and Cost Effectiveness Review
Title: Empirical Therapy with Echinocandins for Suspected Candidemia and Invasive Candidiasis: A Clinical and Cost Effectiveness Review Date: 07 April 2008 Context and policy issues: Candidemia (the presence
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationmycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Dimitrios P. Kontoyiannis, 1 Nkechi Azie, 2 Billy
More informationII Raad, HA Hanna, M Boktour, Y Jiang, HA Torres, C Afif, DP Kontoyiannis and RY Hachem
(2008) 22, 496 503 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Novel antifungal agents as salvage therapy for invasive aspergillosis in patients
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationHistorically, amphotericin B deoxycholate
OUR CURRENT UNDERSTANDING OF THERAPIES FOR INVASIVE FUNGAL INFECTIONS * John R. Perfect, MD ABSTRACT This article provides an update on the current state of the art for treating invasive fungal infections,
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationVoriconazole in Prevention and Treatment of Febrile Neutropenia
2016 jpc.tums.ac.ir Voriconazole in Prevention and Treatment of Febrile Neutropenia Hamidreza Taghva Masoumi 1, Molouk Hadjibabaie 1,2, Kheirollah Gholami 1,2, Maryam Shahrokhi 1* 1 Clinical Pharmacy Department,
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationLiposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients
ORIGINAL ARTICLE MYCOLOGY Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients K. Bochennek 1, L. Tramsen 1, N. Schedler 1, M. Becker 1, T. Klingebiel
More informationInvasive aspergillosis (IA) has emerged as a major cause of morbidity. Aspergillus terreus
1594 Aspergillus terreus An Emerging Amphotericin B Resistant Opportunistic Mold in Patients with Hematologic Malignancies Ray Y. Hachem, M.D. 1 Dimitrios P. Kontoyiannis, M.D., Sc.D. 1 Maha R. Boktour,
More informationEvaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 941-946, 2014 Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B EISEKI USAMI 1, MICHIO KIMURA 1, TETSUFUMI
More informationHigh risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient
More informationInvasive Aspergillosis in Steroid-Treated Patients
Invasive Aspergillosis in Steroid-Treated Patients Dimitrios P. Kontoyiannis, MD, ScD Professor of Medicine Department of Infectious Diseases Infection Control and Employee Health PMN damaging Aspergillus
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationDifficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies
Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies Amar Safdar The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vfend) Reference Number: AZ.CP.PHAR.39 Effective Date: 11.16.16 Last Review Date: 09.11.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationTailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna
Tailored Antifungal Modification in Breakthrough Mold Infections Russell E. Lewis University of Bologna 45 year-old patient with AML and documented pulmonary aspergillosis during remissioninduction chemotherapy
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More informationREVIEW. Haematology, The Royal Free Hospital, London, UK
REVIEW Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy A. Glasmacher 1 and A. Prentice
More informationInvasive fungal infections have become an increasing
A Multicenter, Randomized Trial of Fluconazole versus Amphotericin B for Empiric Antifungal Therapy of Febrile Neutropenic Patients with Cancer* Drew J. Winston, MD, James W. Hathorn, MD, Mindy G. Schuster,
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationIntroduction. J Antimicrob Chemother 2011; 66 Suppl 1: i25 35 doi: /jac/dkq439. Nick Freemantle 1 *, Puvan Tharmanathan 2 and Raoul Herbrecht 3
J Antimicrob Chemother 2011; 66 Suppl 1: i25 35 doi:10.1093/jac/dkq439 Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationAdvance Access published February 22, 2005
Advance Access published February 22, 2005 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkh535 JAC Economic evaluation of voriconazole compared with conventional amphotericin B for the primary
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationMAJOR ARTICLE. Outcomes of Patients with IA and AML-MDS CID 2008:47 (15 December) 1507
MAJOR ARTICLE Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study Lennert
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology oncology patients: a retrospective cohort study Hsiang-Chi
More informationOptimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients
Optimal Management of Invasive Aspergillosis in the Context of New Guidelines in High Risk Haematological Patients Shariq Haider Professor Medicine McMaster University Conflict of Interest Disclosure Slide
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationFungal Infections in Neutropenic Hematological Disorders
Fungal Infections in Neutropenic Hematological Disorders 23 Dr Farah Jijina 24 Fungal Infections in Neutropenic Hematological Disorders 25 Dr Farah Jijina 26 Fungal Infections in Neutropenic Hematological
More informationNew dosing strategies for liposomal amphotericin B in high-risk patients Michael Ellis
REVIEW New dosing strategies for liposomal amphotericin B in high-risk patients Michael Ellis Faculty of Medicine and Health Sciences, UAE Medical School, Al-Ain, United Arab Emirates ABSTRACT In recent
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationTOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018
TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01 Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma,
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationSafety and tolerability of caspofungin acetate in the treatment of fungal infections
C.A. Sable B-Y T. Nguyen J.A. Chodakewitz M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Key words: caspofungin; echinocandin; esophageal candiasis;
More informationRoyce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker
Royce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker Astellas Enzon Pharmaceuticals Merck & Co, Inc. Ortho-McNeil, Inc. Pfizer, Inc. Sanofi Aventis Schering-Plough The
More information